Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?
A. Verma; J. Pedicano; S. Trifilio; S. Singhal; M. Tallman; J. Winter; S. Williams; L. Gordon; J. Monreal; J. Mehta (Profiled Authors: Leo I Gordon; Jayesh Mehta; Seema Singhal; Stephanie Williams; Jane Norma Winter)
Bone Marrow Transplantation. 2004;33(7):715-719.Abstract
Growth factors are routinely used after autotransplantation to accelerate hematopoietic recovery, and are continued until the absolute neutrophil count (ANC) is ≥0.5 × 109/l on 3 consecutive days. Since ANC often increases to very high levels with this strategy, we discontinued growth factor on the first day ANC reached 0.5 × 109/l in 45 patients (Study Group), and compared their subsequent ANC to 108 historic controls who received growth factor longer. While ANC on the day after reaching 0.5 × 109/l was comparable between groups, ANC on the third day was significantly higher in the Control Group (2.3 vs 4.9 × 109/l; P = 0.0003). When compared to the first day, ANC in the Study Group was higher by a median of 140% on the third day and by 450% in the Control Group (P = 0.0002). A significantly higher proportion of patients experienced a decline in ANC after the first day in the Study Group. However, only one patient in the Study Group became neutropenic transiently and ANC recovered spontaneously the next day. The incidence of fever and hospitalization were comparable. We conclude that growth factors can be discontinued after autotransplantation the day the ANC reaches 0.5 × 109/l, without compromising neutrophil recovery. © 2004 Nature Publishing Group All rights reserved.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Hillard M. Lazarus; Janet Andersen; Michael G. Chen; Diane Variakojis; Edward G. Mansour; Dagmar Oette; Cheryl A. Arce; Martin M. Oken; Stanton L. Gerson
Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: Blood and bone marrow progenitor growth studies. A phase II eastern cooperative oncology group trialBlood. 1991;78(3):830-837.
T.M. Zimmerman; W.J. Lee; J.G. Bender; R. Mick; S.F. WilliamsProgress in clinical and biological research. 1994;389:303-308.
S.L. Smith; J.G. Bender; P.B. Maples; K. Unverzagt; M. Schilling; L. Lum; S. Williams; D.E. Van EppsExperimental Hematology. 1993;21(7):870-877.
Appears in this Document